GlaxoSmithKline has decided to pull all of its marketing applications for Rezonic due to the extra trials it would need to carry out on the investigational nausea drug.

The company said it has “made the difficult decision” to discontinue the regulatory filings for Rezonic (casopitant), which in some markets would have been sold as Zunrisa, which was being developed for chemotherapy-induced and post-operative nausea and vomiting. The healthcare giant noted that after regulatory consultation, it became clear that “significant further safety data would be required to support the registration of casopitant on a worldwide basis”.

This would take “a considerable time to produce”, GSK said, hence the decision to pull the applications. This move comes three months after the firm received a complete response letter from the US Food and Drug Administration regarding Rezonic and and at the time GSK limited itself to saying that “questions remain that preclude the approval of the application".

GSK already markets Zofran (ondansetron) to prevent nausea and vomiting caused by surgery or cancer medicines.

Brazil deal completed
Meantime, GSK has completed an interesting deal with the government in Brazil worth 1.5 billion euros which effectively guarantees sales of its pneumococcal vaccine Synflorix for the lifetime of the product.

It means that GSK will provide Synflorix, its 10-valent conjugate vaccine for paediatric pneumococcal disease, at an agreed price and volume, starting at 11.50 euros per dose, about a third of the price charged in Europe, falling to 5 euros. The company will supply enough doses of Synflorix to vaccinate the 13 million children requiring coverage each year for at least eight years, and will then transfer the relevant technology that will allow Brazil to manufacture the vaccine itself.

The deal is linked to an agreement signed with Brazil’s Oswaldo Cruz Foundation (Fiocruz) in August which includes the establishment of a new R&D programme for a vaccine for Dengue fever.

Lucozade in China
GSK also revealed that it has signed an exclusive agreement with President (Shanghai) Trading Co, a unit of Uni-President China Holdings to launch its Lucozade drinks across China.

The Chinese cold beverage market is currently valued at S16 billion) and the market for energy drinks is one of the fastest growing areas of functional drinks. Distribution of Lucozade will begin in early 2010 and GSK and UPCH noted that they are in the “early stages of discussions” on a range of additional opportunities.